Document:

EX-10.7

 Exhibit 10.7 
  

			
	

	 	 41 S. Rio Grande Street

Salt Lake City, UT 84101
 (385)
269-0203
 recursionpharma.com

 March 21, 2021 
 Tina
Larson 
 c/o Recursion Pharmaceuticals, Inc. 
 41 S Rio Grande
Street 
 Salt Lake City, UT 84101 
 Re: Confirmatory
Employment Letter 
 Dear Tina: 
 This
letter agreement (the “Agreement”) is entered into between the undersigned (“you”) and Recursion Pharmaceuticals, Inc. (the “Company” or “we”). This Agreement is effective as of the
date you sign it, as indicated below. The purpose of this Agreement is to confirm the current terms and conditions of your employment. 
 1.
Position. Your position will continue to be President and Chief Operating Officer, and you will continue to report to the Company’s Chief Executive Officer. This is a full-time position. You will perform the duties and have the
responsibilities and authority customarily performed and held by an employee in your position or as otherwise may be assigned or delegated to you by the Company. While you render services to the Company, you will not engage in any other employment,
consulting or other business activity (whether full-time or part-time) that would create a conflict of interest with the Company, except as approved by the Company’s Board of Directors (the
“Board”) or otherwise contemplated by Schedule 1. By signing this Agreement, you reconfirm to the Company that you have no contractual commitments or other legal obligations that would prohibit you from performing your
duties for the Company. 
 2. Base Salary. Your current annual base salary is $402,000 increasing to $440,000 effective upon the IPO
Effective Date, which will be payable, less applicable withholdings and deductions, in accordance with the Company’s normal payroll practices. Your annual base salary will be subject to review and adjustment based upon the Company’s normal
performance review practices. The “IPO Effective Date” means the effective date of the Company’s registration statement relating to the Company’s initial public offering. 

3. Annual Bonus. You are eligible to earn an annual cash bonus with a target value of 25% of your annual base salary, based on achieving
performance objectives established by the Board or an authorized committee thereof (the “Committee”) in its sole discretion and payable upon achievement of those objectives as determined by the Committee. If any portion of such
bonus is earned, it will be paid when practicable after the Committee determines it has been earned, subject to you remaining employed with the Company through the payment date. Your annual bonus opportunity will be subject to review and adjustment
based upon the Company’s normal performance review practices. 

 4. Equity Awards. You will be eligible to receive awards of stock options, restricted
stock units or other equity awards pursuant to any plans or arrangements the Company may have in effect from time to time. The Committee will determine in its discretion whether you will be granted any such equity awards and the terms of any such
award in accordance with the terms of any applicable plan or arrangement that may be in effect from time to time. 
 5. Employee
Benefits. As a regular full time, employee of the Company, you will continue to be eligible to participate in Company-sponsored benefits in accordance with the terms of the Company’s policies and benefits plan. In addition, you will
continue to be entitled to paid vacation in accordance with the Company’s vacation policy, as in effect from time to time. Information regarding coverage, eligibility, and other information regarding these benefits is set forth in more detailed
documents that are available from the Company. With the exception of the Company’s at-will employment policy, discussed below, the Company may, from time to time, in its sole discretion, modify or
eliminate its policies and/or benefits offered to employees. 
 6. Severance. You will be eligible for the Company’s Executive
Change in Control and Severance Plan (the “Severance Plan”) beginning of the IPO Effective Date. Your Participation Agreement under the Severance Plan will specify the severance payments and benefits you could be eligible to receive
in connection with certain terminations of your employment with the Company. These protections will supersede all other severance payments and benefits you would otherwise currently be eligible for to, or would become eligible for in the future,
under any plan, program or policy that the Company may have in effect from time to time. 
 7. Employee Confidentiality and Invention
Assignment. As an employee of the Company, you will continue to have access to certain confidential information of the Company and you may, during the course of your employment, develop certain information or inventions that will be the property
of the Company. To protect the interests of the Company, your acceptance of this Agreement confirms that the terms of the Company’s At-Will Employment, Confidential Information, Invention Assignment, and
Arbitration Agreement you previously signed with the Company (the “Confidentiality Agreement”) still apply. 
 8.
Employment Relationship. Employment with the Company will continue to be for no specific period of time. Your employment with the Company will continue to be “at will,” meaning that either you or the Company may terminate your
employment at any time and for any reason, with or without cause. Any contrary representations that may have been made to you are superseded by this Agreement. This is the full and complete agreement between you and the Company on this term.
Although your job duties, title, compensation and benefits, as well as the Company’s personnel policies and procedures, may change from time to time, the “at will” nature of your employment may only be changed in an express written
agreement signed by you and a duly authorized officer of the Company (other than you). 

  
 -2- 

 9. FDA Disbarment. As a condition of the acceptance of this Agreement, you certify
that you are not and have never been debarred by the FDA pursuant to 21 USC 335, are not listed on the FDA’s disqualified/restricted list, are not excluded from participating in federal health care programs, and have not committed any actions
that could lead to FDA debarment or exclusion from federal health care programs. If you become aware of a proceeding that could lead to debarment or disqualification/restriction by FDA or exclusion from federal health care programs, you will
immediately inform the Board. 
 10. Protected Activity Not Prohibited. Nothing in this Agreement or in any other agreement between
you and the Company, as applicable, will in any way limit or prohibit you from engaging for a lawful purpose in any Protected Activity. For purposes of this Agreement, “Protected Activity” means filing a charge or complaint, or
otherwise communicating, cooperating, or participating with, any state, federal, or other governmental agency, including but not limited to the U.S. Securities and Exchange Commission, the Equal Employment Opportunity Commission, and the National
Labor Relations Board. Notwithstanding any restrictions set forth in this Agreement or in any other agreement between you and the Company, as applicable, you understand that you are not required to obtain authorization from the Company prior to
disclosing information to, or communicating with, such agencies, nor are you obligated to advise the Company as to any such disclosures or communications. In making any such disclosures or communications, you agree to take all reasonable precautions
to prevent any unauthorized use or disclosure of any information that may constitute Company Confidential Information (within the meaning of the Confidentiality Covenant Agreement) to any parties other than the relevant government agencies. You
further understand that Protected Activity does not include the disclosure of any Company attorney-client privileged communications, and that any such disclosure without the Company’s written consent will constitute a material breach of this
Agreement. You acknowledge that the Company has provided you with notice in compliance with the Defend Trade Secrets Act of 2016 regarding immunity from liability for limited disclosures of trade secrets. The full text of the notice is attached in
Exhibit A. 
 11. Governing Law; Venue. All questions concerning the construction, validity and interpretation of this
Agreement and the exhibits hereto shall be governed by and construed in accordance with the domestic laws of the State of Utah, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Utah or any
other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Utah. Any lawsuit arising out of or in any way related to this Agreement to the Parties’ relationship hereunder shall be brought only
in those state or federal courts having jurisdiction over actions arising in Salt Lake County in the State of Utah. 
 12.
Miscellaneous. This Agreement, the Severance Plan, the Participation Agreement, and the Confidentiality Agreement constitute the entire agreement between you and the Company regarding the subject matters discussed, and they supersede all
prior negotiations, representations or agreements between you and the Company. This Agreement may only be modified by a written agreement signed by you and the Company’s Chief Executive Officer. 

  
 -3- 

 To confirm the current terms and conditions of your employment, please sign and date in the
spaces indicated and return this Agreement to the Company. 
  

			
	Sincerely,
	
	Recursion Pharmaceuticals, Inc.
		
	By:	 	 /s/ Christopher Gibson___

	Christopher Gibson
	Chief Executive Officer

 I have read and understood this Agreement and hereby acknowledge, accept and agree to the terms as set
forth herein and further acknowledge that no other commitments were made to me as part of my employment offer except as specifically set forth herein. 
  

	
	 /s/ Tina Larson

	Tina Larson
	Date: March 22, 2021

  
 -4- 

 Exhibit A 

SECTION 7 OF THE DEFEND TRADE SECRETS ACT OF 2016 

“ . . . An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a
trade secret that—(A) is made—(i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation
of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. . . . An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law
may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual—(A) files any document containing the trade secret under seal; and (B) does not disclose the
trade secret, except pursuant to court order.” 

  
 -5-EX-10.8

 Exhibit 10.8 
  

			
	

	 	 41 S. Rio Grande Street

Salt Lake City, UT 84101
 (385)
269-0203
 recursionpharma.com

 March 21, 2021 
 Michael
Secora 
 c/o Recursion Pharmaceuticals, Inc. 
 41 S Rio Grande
Street 
 Salt Lake City, UT 84101 
 Re: Confirmatory
Employment Letter 
 Dear Michael: 
 This
letter agreement (the “Agreement”) is entered into between the undersigned (“you”) and Recursion Pharmaceuticals, Inc. (the “Company” or “we”). This Agreement is effective as of the
date you sign it, as indicated below. The purpose of this Agreement is to confirm the current terms and conditions of your employment. 
 1.
Position. Your position will continue to be Chief Financial Officer, and you will continue to report to the Company’s Chief Executive Officer. This is a full-time position. You will perform the duties and have the responsibilities and
authority customarily performed and held by an employee in your position or as otherwise may be assigned or delegated to you by the Company. While you render services to the Company, you will not engage in any other employment, consulting or other
business activity (whether full-time or part-time) that would create a conflict of interest with the Company, except as approved by the Company’s Board of Directors (the “Board”) or
otherwise contemplated by Schedule 1. By signing this Agreement, you reconfirm to the Company that you have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company. 

2. Base Salary. Your current annual base salary is $205,000 increasing to $350,000 effective upon the IPO Effective Date, which will be
payable, less applicable withholdings and deductions, in accordance with the Company’s normal payroll practices. Your annual base salary will be subject to review and adjustment based upon the Company’s normal performance review practices.
The “IPO Effective Date” means the effective date of the Company’s registration statement relating to the Company’s initial public offering. 

 3. Annual Bonus. You are eligible to earn an annual cash bonus with a target value of
25% of your annual base salary, based on achieving performance objectives established by the Board or an authorized committee thereof (the “Committee”) in its sole discretion and payable upon achievement of those objectives as
determined by the Committee. If any portion of such bonus is earned, it will be paid when practicable after the Committee determines it has been earned, subject to you remaining employed with the Company through the payment date. Your annual bonus
opportunity will be subject to review and adjustment based upon the Company’s normal performance review practices. 
 4. Equity
Awards. You will be eligible to receive awards of stock options, restricted stock units or other equity awards pursuant to any plans or arrangements the Company may have in effect from time to time. The Committee will determine in its discretion
whether you will be granted any such equity awards and the terms of any such award in accordance with the terms of any applicable plan or arrangement that may be in effect from time to time. 

5. Employee Benefits. As a regular full time, employee of the Company, you will continue to be eligible to participate in
Company-sponsored benefits in accordance with the terms of the Company’s policies and benefits plan. In addition, you will continue to be entitled to paid vacation in accordance with the Company’s vacation policy, as in effect from time to
time. Information regarding coverage, eligibility, and other information regarding these benefits is set forth in more detailed documents that are available from the Company. With the exception of the Company’s
at-will employment policy, discussed below, the Company may, from time to time, in its sole discretion, modify or eliminate its policies and/or benefits offered to employees. You will be eligible to
participate in the Company’s 401(k) plan pursuant to its terms and conditions; provided, however, that if you make the maximum amount of contributions to the Company’s 401(k) plan (the “401(k) Plan”) permitted under the
Internal Revenue Code of 1986, as amended (the “Code”) in any particular year, the Company will make a contribution to another retirement plan equal to (i) the maximum amount of Employer 401(k) Plan Contributions that the
Company is permitted to make under the Code for such year minus (ii) the actual amount of Employer 401(k) Plan Contributions that that the Company makes for such year. “Employer 401(k) Plan Contributions” means contributions to
the 401(k) Plan made by the Company for your benefit. For example, if you contribute to the 401(k) Plan in 2021 the maximum amount of $19,500, the Company will make a contribution to such other retirement plan an amount equal to (i) $38,500 (which
is the maximum amount of Employer 401(k) Plan Contributions for 2021) minus (ii) the actual amount of Employer 401(k) Plan Contributions that the Company makes for 2021. The Company will establish such other retirement plan in consultation with
you, subject to all applicable laws and regulations. 
 6. Severance. You will be eligible for the Company’s Executive Change in
Control and Severance Plan (the “Severance Plan”) beginning of the IPO Effective Date. Your Participation Agreement under the Severance Plan will specify the severance payments and benefits you could be eligible to receive in
connection with certain terminations of your employment with the Company. These protections will supersede all other severance payments and benefits you would otherwise currently be eligible for to, or would become eligible for in the future, under
any plan, program or policy that the Company may have in effect from time to time. 

  
 -2- 

 7. Employee Confidentiality and Invention Assignment. As an employee of the Company,
you will continue to have access to certain confidential information of the Company and you may, during the course of your employment, develop certain information or inventions that will be the property of the Company. To protect the interests of
the Company, your acceptance of this Agreement confirms that the terms of the Company’s At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement you previously signed
with the Company (the “Confidentiality Agreement”) still apply. 
 8. Employment Relationship. Employment with the
Company will continue to be for no specific period of time. Your employment with the Company will continue to be “at will,” meaning that either you or the Company may terminate your employment at any time and for any reason, with or
without cause. Any contrary representations that may have been made to you are superseded by this Agreement. This is the full and complete agreement between you and the Company on this term. Although your job duties, title, compensation and
benefits, as well as the Company’s personnel policies and procedures, may change from time to time, the “at will” nature of your employment may only be changed in an express written agreement signed by you and a duly authorized
officer of the Company (other than you). 
 9. FDA Disbarment. As a condition of the acceptance of this Agreement, you certify that
you are not and have never been debarred by the FDA pursuant to 21 USC 335, are not listed on the FDA’s disqualified/restricted list, are not excluded from participating in federal health care programs, and have not committed any actions that
could lead to FDA debarment or exclusion from federal health care programs. If you become aware of a proceeding that could lead to debarment or disqualification/restriction by FDA or exclusion from federal health care programs, you will immediately
inform the Board. 
 10. Protected Activity Not Prohibited. Nothing in this Agreement or in any other agreement between you and the
Company, as applicable, will in any way limit or prohibit you from engaging for a lawful purpose in any Protected Activity. For purposes of this Agreement, “Protected Activity” means filing a charge or complaint, or otherwise
communicating, cooperating, or participating with, any state, federal, or other governmental agency, including but not limited to the U.S. Securities and Exchange Commission, the Equal Employment Opportunity Commission, and the National Labor
Relations Board. Notwithstanding any restrictions set forth in this Agreement or in any other agreement between you and the Company, as applicable, you understand that you are not required to obtain authorization from the Company prior to disclosing
information to, or communicating with, such agencies, nor are you obligated to advise the Company as to any such disclosures or communications. In making any such disclosures or communications, you agree to take all reasonable precautions to prevent
any unauthorized use or disclosure of any information that may constitute Company Confidential Information (within the meaning of the Confidentiality Covenant Agreement) to any parties other than the relevant government agencies. You further
understand that Protected Activity does not include the disclosure of any Company attorney-client privileged communications, and that any such disclosure without the Company’s written consent will constitute a material breach of this Agreement.
You acknowledge that the Company has provided you with notice in compliance with the Defend Trade Secrets Act of 2016 regarding immunity from liability for limited disclosures of trade secrets. The full text of the notice is attached in Exhibit
A. 

  
 -3- 

 11. Governing Law; Venue. All questions concerning the construction, validity and
interpretation of this Agreement and the exhibits hereto shall be governed by and construed in accordance with the domestic laws of the State of Utah, without giving effect to any choice of law or conflict of law provision or rule (whether of the
State of Utah or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Utah. Any lawsuit arising out of or in any way related to this Agreement to the Parties’ relationship hereunder
shall be brought only in those state or federal courts having jurisdiction over actions arising in Salt Lake County in the State of Utah. 

12. Miscellaneous. This Agreement, the Severance Plan, the Participation Agreement, and the Confidentiality Agreement constitute the
entire agreement between you and the Company regarding the subject matters discussed, and they supersede all prior negotiations, representations or agreements between you and the Company. This Agreement may only be modified by a written agreement
signed by you and the Company’s Chief Executive Officer. 

  
 -4- 

 To confirm the current terms and conditions of your employment, please sign and date in the
spaces indicated and return this Agreement to the Company. 
  

			
	Sincerely,
	
	Recursion Pharmaceuticals, Inc.
		
	By:	 	 /s/ Christopher Gibson

	Christopher Gibson
	Chief Executive Officer

 I have read and understood this Agreement and hereby acknowledge, accept and agree to the terms as set
forth herein and further acknowledge that no other commitments were made to me as part of my employment offer except as specifically set forth herein. 
  

	
	 /s/ Michael Secora

	Michael Secora
	Date: March 22, 2021

  
 -5- 

 Exhibit A 

SECTION 7 OF THE DEFEND TRADE SECRETS ACT OF 2016 

“ . . . An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a
trade secret that—(A) is made—(i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation
of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. . . . An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law
may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual—(A) files any document containing the trade secret under seal; and (B) does not disclose the
trade secret, except pursuant to court order.” 

  
 -6-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]